BSH 2017 | How the treatment of AML will change
Mary F. McMullin
Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
1:01
Metabolic profiling of the leukemia stem cell
Giovanni Martinelli
1:33
PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies
Giovanni Martinelli
3:56
RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML
Richard Thomas Maziarz
3:06
Improved understanding of CPX-351 in AML: impact of HCT & final EAP results
Tara Lin
